Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Caligan Partners LP and David Johnson report beneficial ownership of Opus Genetics, Inc. common stock on a passive Schedule 13G/A basis. They collectively report 6,077,084 shares of common stock, representing 7.3% of the class.
The ownership percentage is based on 83,195,823 shares of Opus Genetics common stock outstanding as of August 3, 2026, as reported by the company for the quarter ended June 30, 2026. All reported shares are held with shared voting and dispositive power through Caligan-managed funds and accounts.
Key Figures
Beneficial ownership:6,077,084 sharesPercent of class:7.3%Shares outstanding:83,195,823 shares+2 more
5 metrics
Beneficial ownership6,077,084 sharesShares of Opus Genetics common stock reported by Caligan Partners and David Johnson
Percent of class7.3%Portion of Opus Genetics common stock class beneficially owned by the reporting persons
Shares outstanding83,195,823 sharesOpus Genetics common stock outstanding as of August 3, 2026, per Form 10-Q
Shared voting power6,077,084 sharesShares over which the reporting persons have shared power to vote or direct the vote
Shared dispositive power6,077,084 sharesShares over which the reporting persons have shared power to dispose or direct disposition
"Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting powerfinancial
"Shared Voting Power 6,077,084.00 7 | Sole Dispositive Power 0.00 8 | Shared Dispositive"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Voting Power 6,077,084.00 7 | Sole Dispositive Power 0.00 8 | Shared Dispositive"
Reporting Personregulatory
"Each of the foregoing is referred to as a "Reporting Person" and collectively as the"
percent of classfinancial
"Percent of class: 7.3% (c) | Number of shares as to which the person has"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Opus Genetics, Inc. (IRD) does Caligan Partners own?
Caligan Partners and David Johnson report beneficial ownership of 7.3% of Opus Genetics’ common stock. This corresponds to 6,077,084 shares, calculated against 83,195,823 shares outstanding as of August 3, 2026.
How many Opus Genetics (IRD) shares are reported as beneficially owned?
The reporting persons disclose beneficial ownership of 6,077,084 shares of Opus Genetics common stock. This stake represents 7.3% of the company’s outstanding common stock, based on 83,195,823 shares outstanding on August 3, 2026.
Who are the reporting persons in this Opus Genetics (IRD) Schedule 13G/A?
The Schedule 13G/A is filed by Caligan Partners LP and David Johnson. Caligan is the investment manager to certain funds and accounts holding the shares, and David Johnson is Caligan’s Managing Partner and a United States citizen.
What voting and dispositive power do Caligan and David Johnson have over Opus Genetics (IRD) shares?
The reporting persons state 0 shares with sole voting or dispositive power and 6,077,084 shares with shared voting and shared dispositive power, held through Caligan-managed funds and accounts.
What share count did Opus Genetics (IRD) report as outstanding for this ownership calculation?
The 7.3% ownership figure is based on 83,195,823 shares of Opus Genetics common stock outstanding as of August 3, 2026, as reported in the company’s Form 10-Q for the quarter ended June 30, 2026.
Where are Caligan Partners and David Johnson based in relation to their Opus Genetics (IRD) holdings?
The principal business address for both reporting persons is 780 Third Avenue, 30th Floor, New York, NY 10017. Caligan is organized in Delaware, and David Johnson is a United States citizen.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Opus Genetics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
67577R102
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
Caligan Partners LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,077,084.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,077,084.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,077,084.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.3 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
67577R102
1
Names of Reporting Persons
JOHNSON DAVID EDWARD
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,077,084.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,077,084.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,077,084.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.3 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Opus Genetics, Inc.
(b)
Address of issuer's principal executive offices:
8 DAVIS DRIVE, SUITE 220, DURHAM, NORTH CAROLINA, 27713
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Caligan Partners LP, a Delaware limited partnership ("Caligan"), which serves indirectly as the investment manager to certain funds and accounts (the "Caligan Funds and Accounts"), with respect to the shares of common stock, $0.0001 par value per share ("Common Stock") of Opus Genetics, Inc., a Delaware corporation (the "Company"), held by the Caligan Funds and Accounts; and
(ii) David Johnson, the Managing Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan ("Mr. Johnson"), with respect to the shares of Common Stock held by the Caligan Funds and Accounts.
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)
Address or principal business office or, if none, residence:
The principal business address of each of the Reporting Persons is 780 Third Avenue, 30th Floor, New York, NY 10017.
(c)
Citizenship:
Caligan is a Delaware limited partnership. Mr. Johnson is a United States citizen.
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
67577R102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentages set forth in this Schedule 13G are calculated based upon an aggregate of 83,195,823 shares of Common Stock outstanding as of August 3, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026.
(b)
Percent of class:
7.3%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
